Want to see MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
$0.08
>-$0.01(-6.89%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-6.89%)
Day’s Range― - ―
52-Week Range$0.05 - $0.16
Previous CloseN/A
Volume256.86K
Average Volume (3M)638.59K
Market Cap
$21.32M
Enterprise Value$115.28M
Total Cash (Recent Filing)$8.44M
Total Debt (Recent Filing)$90.68M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding403,740,500
10 Day Avg. Volume482,779
30 Day Avg. Volume638,589
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap5.41
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit1.98
Enterprise Value/Ebitda11.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$161.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRecord quarterly revenue and continued year-over-year growth indicate ongoing demand across MariMed’s retail and wholesale channels. Sustained top-line expansion can support operating leverage, fund product development, and strengthen the company’s position as newer markets and locations scale.
Brand And Distribution StrengthBroader storefront distribution and above-industry branded-portfolio growth suggest improving product reach and commercial relevance. Stronger brand penetration can support repeat purchases, wholesale pull-through, and more durable competitive positioning across regulated state markets.
Positive Operating Cash FlowPositive operating and free cash flow provide an important source of internal funding while the company expands its operations. Although consistency still matters, improved cash generation can reduce reliance on external capital and support investment in cultivation, products, and dispensary growth.
Bears Say
Elevated LeverageHigher leverage and declining equity reduce financial flexibility and leave less capacity to absorb operating setbacks or fund expansion internally. The increased debt burden also heightens refinancing and interest-rate sensitivity, making balance-sheet improvement important to longer-term resilience.
Persistent Losses And Margin CompressionContinued net losses and lower margins show that revenue growth has not yet translated into durable earnings improvement. Persistent profitability pressure can constrain reinvestment, weaken debt-servicing capacity, and make future results more dependent on successful cost control and operational scaling.
Pricing And Market Saturation PressureIndustry pricing declines and localized saturation can weigh on realized revenue per transaction and gross margins even when sales volumes grow. Ongoing promotional intensity may limit the benefits of expansion, particularly in crowded markets, and makes sustainable margin recovery dependent on differentiation and customer loyalty.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.05 and its highest was $0.16 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $21.32M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is Nov 11, 2026 which is in 18 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Aug 12, 2026. The company reported -$0.007 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.003.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Overvalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 403,740,500 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of -$0.007 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MariMed Inc
MariMed Inc. operates in the cannabis industry, specializing in the cultivation, production, and sale of both medicinal and adult-use cannabis items throughout the United States and internationally. The company's diverse product portfolio includes cannabis flowers and concentrates marketed under the Nature's Heritage brand. It also offers infused goods such as chewable tablets and powdered drink mixes under the Kalm Fusion label, natural fruit chews known as Betty's Eddies, and a line of baked treats like brownies and cookies available through Bubby's Baked. Furthermore, MariMed develops cannabidiol (CBD) products under the Florance brand. Beyond its own offerings, the company licenses its various brands and product formulations to others and leases facilities designed for cannabis operations. MariMed Inc., founded in 2011, is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and commercial momentum: record quarterly revenue, sequential EBITDA improvement, expanding brand distribution, strong retail transaction growth and rising loyalty membership. These positives are tempered by meaningful year-over-year margin and EBITDA declines driven by industry-wide price compression, elevated promotional activity and localized market saturation (notably Massachusetts). Management characterizes many margin headwinds as transitional and highlights upcoming catalysts (Ohio dispensary, New York entry, improved cultivation utilization, potential regulatory relief) to support future margin expansion.View all MRMD earnings summariesTechnical Analysis
Ownership Overview
10.83% Insiders
0.18% Other Institutional Investors
88.99% Public Companies and
Individual Investors